These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33338946)

  • 1. Time interval between disease onset and MS diagnosis during the last decades in Latin America.
    Rojas JI; Carnero Contentti E; Henestroza P; Giachello S; Correale J
    Mult Scler Relat Disord; 2021 Feb; 48():102672. PubMed ID: 33338946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization.
    Correale J; Abad P; Alvarenga R; Alves-Leon S; Armas E; Barahona J; Buzó R; Corona T; Cristiano E; Gracia F; Bonitto JG; Macías MA; Soto A; Vizcarra D; Freedman MS
    J Neurol Sci; 2014 Apr; 339(1-2):196-206. PubMed ID: 24607335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement over previous decades in time of diagnosis but not in time of initiating DMD in MS patients in Argentina.
    Rojas JI; Patrucco L; Pappolla A; Cristiano E
    Mult Scler Relat Disord; 2021 Jul; 52():103007. PubMed ID: 34000685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time interval between the onset of symptoms and diagnosis of multiple sclerosis and the influential factors: A national registry-based study.
    Khodaie F; Moghadasi AN; Hosseinnataj A; Baghbanian SM; Ashtari F; Razazian N; Poursadeghfard M; Majdi-Nasab N; Hatamian H; Hoseini S; Nahayati MA; Nabavi SM; Faraji F; Harirchian MH; Mir NHN; Moghadam NB; Sharifipour E; Bayati A; Kamali H; Mozhdehipanah H; Jalali N; Abotorabi-Zarchi M; Kamyari N; Nikbakht R; Azimi A; Navardi S; Heidari H; Sahraian MA; Eskandarieh S
    Clin Neurol Neurosurg; 2024 Apr; 239():108221. PubMed ID: 38447483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades.
    Romero-Pinel L; Bau L; Matas E; León I; Muñoz-Vendrell A; Arroyo P; Masuet-Aumatell C; Martínez-Yélamos A; Martínez-Yélamos S
    Mult Scler Relat Disord; 2022 Dec; 68():104103. PubMed ID: 36029708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interobserver agreement on Poser's and the new McDonald's diagnostic criteria for multiple sclerosis.
    Zipoli V; Portaccio E; Siracusa G; Pracucci G; Sorbi S; Amato MP
    Mult Scler; 2003 Oct; 9(5):481-5. PubMed ID: 14582774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America.
    Cristiano E; Rojas JI; Abad P; Adoni T; Barahona J; Becker J; Carrá A; Flores J; Fruns M; Fernández Liguori N; Garcea O; García Bónito J; Giunta D; Gracia F; Hamuy F; Macias Islas MA; Navas C; Boschetti LO; Patrucco L; Sato DK; Correale J
    J Neurol Sci; 2018 Oct; 393():4-13. PubMed ID: 30096568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MS in Latin America.
    Luetic G
    Int MS J; 2008 Mar; 15(1):6-11. PubMed ID: 18713563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research priorities in multiple sclerosis in Latin America: A multi-stakeholder call to action to improve patients care: Research priorities in MS in LATAM.
    Rojas JI; Carnero Contentti E; Abad P; Aguayo A; Alonso R; Bauer J; Becker J; Bustos AK; Carcamo CA; Carra A; Correa Diaz EP; Correale J; Cristiano E; Diaz AJ; Fernandez Liguori N; Flores J; Fruns M; Garcea O; Giachello SM; Godoy MD; Gracia F; Hamuy VF; Henestroza PR; Navarra JA; Navas C; Patrucco L; Perez Bruno M; Prato AS; Rivera VM; Rosa Martinez AR; Vanotti S; Vazquez M; Vizcarra D; Ysrraelit MC; Alonso Serena M;
    Mult Scler Relat Disord; 2021 Aug; 53():103038. PubMed ID: 34090128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey of Latin American Neuroimmunologists on the Treatment of Multiple Sclerosis with Monoclonal Antibodies.
    Fragoso YD
    Curr Drug Saf; 2015; 10(3):217-20. PubMed ID: 25895725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of multiple sclerosis in Iraq: retrospective review of 4355 cases and literature review.
    Hassoun HK; Al-Mahadawi A; Sheaheed NM; Sami SM; Jamal A; Allebban Z
    Neurol Res; 2022 Jan; 44(1):14-23. PubMed ID: 34409919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis.
    Naseri A; Nasiri E; Sahraian MA; Daneshvar S; Talebi M
    Mult Scler Relat Disord; 2021 May; 50():102816. PubMed ID: 33571792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed diagnosis of multiple sclerosis in a low prevalence country.
    Cárdenas-Robledo S; Lopez-Reyes L; Arenas-Vargas LE; Carvajal-Parra MS; Guío-Sánchez C
    Neurol Res; 2021 Jul; 43(7):521-527. PubMed ID: 33357115
    [No Abstract]   [Full Text] [Related]  

  • 14. The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review.
    Cristiano E; Rojas J; Romano M; Frider N; Machnicki G; Giunta D; Calegaro D; Corona T; Flores J; Gracia F; Macias-Islas M; Correale J
    Mult Scler; 2013 Jun; 19(7):844-54. PubMed ID: 23045380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
    Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R
    Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.
    Montalban X; Sastre-Garriga J; Filippi M; Khaleeli Z; Téllez N; Vellinga MM; Tur C; Brochet B; Barkhof F; Rovaris M; Miller DH; Polman CH; Rovira A; Thompson AJ
    Mult Scler; 2009 Dec; 15(12):1459-65. PubMed ID: 19995843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence and utility of screening for urinary tract infection at the time of presumed multiple sclerosis relapse.
    Fitzgerald KC; Cassard LA; Fox SR; Probasco JC; Cassard SD; Mowry EM
    Mult Scler Relat Disord; 2019 Oct; 35():61-66. PubMed ID: 31344604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid foot-tapping but not hand-tapping ability is different between relapsing-remitting and progressive multiple sclerosis.
    Sato S; Lim J; Miehm JD; Buonaccorsi J; Rajala C; Khalighinejad F; Ionete C; Kent JA; van Emmerik REA
    Mult Scler Relat Disord; 2020 Jun; 41():102031. PubMed ID: 32172213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS.
    Tomassini V; De Giglio L; Reindl M; Russo P; Pestalozza I; Pantano P; Berger T; Pozzilli C
    Mult Scler; 2007 Nov; 13(9):1086-94. PubMed ID: 17468447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.